Legal Opinion
In Re Brand-Name Prescription Drugs Antitrust Litigation
United States Judicial Panel on Multidistrict Litigation
Decided October 19, 2001No. MDL-997PublishedCited by 14 opinions
1Opinion of the Court
REMAND ORDER
WILLIAM TERRELL HODGES, Chairman.
This matter is before the Panel on the defendants’ 1 motion, pursuant to Rule 7.6, R.P.J.P.M.L., 199 F.R.D. 425, 436-38 (2001), to vacate the Panel’s order separating the Sherman Antitrust Act claims from the Robinson-Patman Act claims in the actions listed on Schedule A and conditionally remanding the Sherman Act claims to their respective transferor courts as suggested in an order entered by the transferee court. All responding plaintiffs oppose the motion to vacate and support remand of these claims.
On the basis of the papers filed and hearing…
2Cases cited2 opinions
- In Re Holiday Magic Securities & Antitrust LitigationUnited States Judicial Panel on Multidistrict Litigation · 1977
- In Re IBM Peripheral EDP Devices Antitrust LitigationUnited States Judicial Panel on Multidistrict Litigation · 1976
3Cited by14 opinions
- In Re Brand-Name Prescription Drugs Antitrust LitigationUnited States Judicial Panel on Multidistrict Litigation · 2003
- In re Light Cigarettes Marketing Sales Practices LitigationDistrict Court, D. Maine · 2011
- Adams v. Equifax, Inc.District Court, N.D. Georgia · 2022
- Audella Patterson v. Equifax, Inc.District Court, N.D. Georgia · 2022
- Dunn v. Takata Corporation [Economic Loss Class Actions]District Court, S.D. Florida · 2020
9 more not listed; retrieve them via the Exa API.